In each of the 7 French areas that should be involved, patients aged 75 years and over from three different sectors will be included: the geriatric consultation unit (60%) and two kinds of nursing homes, private (20%) and state (10%). Outpatients will be included in chronological order; patients in nursing homes will be included at random. The patients and their families will be asked about the treatments received on the day of inclusion. The inclusion period will extend over a year. The investigating practitioners will be asked to fill in a questionnaire reporting the main clinical data, adverse effects occurrence, and information on the treatment given.
Study Type
OBSERVATIONAL
Enrollment
636
CHU Rouen
Rouen, Bois Guillaume, France
CHU Bordeaux
Pessac, Bordeaux, France
CH Le Mans
Le Mans, Le Mans Cedex 1, France
CHU Montpellier
Montpellier, Montpellier Cedex 5, France
APHP Charles Foix
Ivry-sur-Seine, Paris, France
CHU Saint Etienne
Saint-Etienne, Saint Etienne, France
To evaluate the prevalence of PIM use in patients aged 75 years and over treated with anticholinesterase and/or memantine
Time frame: 2 years
To identify factors associated with PIM use. To study the relationship between PIM exposure and adverse effects occurrence.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.